Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Synthetic Blood (SYBD) -- Ignore unavailable to you. Want to Upgrade?

To: Rick Hoffmann who wrote (182)	5/27/1998 9:27:00 AM
From: Eric Beckman	Read Replies (2) \| Respond to of 307

The following was released this morning: Wednesday May 27, 9:01 am Eastern Time Company Press Release Howard Jones, Ph.D., Appointed to Board of Synthetic Blood International KETTERING, Ohio--(BUSINESS WIRE)--May 27, 1998--Howard Jones, Ph.D., president of the biopharmaceutical business unit of Curative Health Services has been appointed to the board of directors of Synthetic Blood International Inc., (SYBD). He started his career with Merck Research Laboratories where he discovered Clinoril, a rheumatoid arthritis drug with annual sales of $400 million. At Curative, Dr. Jones is responsible for R&D plus licensing, selling and manufacturing their wound healing technology that incorporates growth factors from the patients own blood. Dr. Jones has more than 84 U.S. patents issued for his biopharmaceutical developments. He has more than 30 years experience in directing research and development of new drugs at Revlon, Bristol-Myers Squibb, Amylin Pharmaceuticals and Cypros Pharmaceuticals, a San Diego-based company he co-founded in 1992. ''Dr. Jones brings the vast experience of directing and managing more than 40 regulatory submissions to the Food and Drug Administration,'' said Robert Nicora, Synthetic Blood International president and chief executive officer. ''His experience in securing financing from venture partners at Cypros, a development stage company similar to Synthetic Blood and at Curative is invaluable.'' Dr. Jones was a Fullbright Scholar. He served as research assistant in the chemistry department at UCLA after graduating with honors from the University of Leeds in England. He is a member of the Royal Society of Medicine, the American Chemical Society, the Chemical Society of England and the New York Academy of Sciences. Nicora, who joined the company in March, was also appointed to serve as a director at the May meeting of the board of directors. SYBD is developing Fluorovent, to assist breathing in patients with lung problems, Oxycyte, a substitute oxygen carrier in the blood stream and an implantable biosensor for continuously noninvasive monitoring of blood glucose levels in diabetics. SYBD is located in Kettering, Ohio. The Company's stock is traded on the OTC Electronic Bulletin Board, symbol SYBD. Contact: Synthetic Blood International Inc. Joan Mahan, 800/809-6054